Intercept Pharmaceuticals, Inc.
Feb 17, 2017

Intercept to Report 2016 Full Year Financial Results on February 23 and Present at Upcoming Conferences

NEW YORK, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its fourth quarter and full year 2016 financial results prior to the NASDAQ market open on Thursday, February 23, 2017. Intercept management will conduct a conference call and audio webcast on Thursday, February 23, 2017 at 8:30 a.m. Eastern Time to discuss these results.

Intercept management will also be presenting at the following investor conferences:

Webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.

CONTACT: For more information about

Intercept Pharmaceuticals, please contact:
       

Intercept Pharmaceuticals:

Mark Vignola

+1-646-747-1000

investors@interceptpharma.com

     
Media inquiries: media@interceptpharma.com
     
Investor inquiries: investors@interceptpharma.com